persons receiving antiretroviral treatment (ART) have also been shown to exhibit greater atherosclerotic disease compared with their HIV-negative counterparts. Cardiovascular disease is likely to increase with enhanced longevity in HIV-positive persons on highly active antiretroviral therapy.

The mechanisms by which HIV infection causes thrombosis are multifactorial and complex.1 HIV-associated factors, as opposed to traditional risk factors (eg, smoking, immobility, family history, hospitalization), are believed to be central to the pathogenesis of thrombosis. Several coagulation abnormalities have been reported among HIV-infected patients including the presence of antiphospholipid antibodies, increased levels of von Willebrand factor, elevated homocysteine, and deficiencies of protein C, protein S, anti-thrombin III, and heparin cofactor II.2 Previous studies suggest that ART, in particular HIV protease inhibitors, negatively impacts the cardiovascular system.2 However, there are also several publications in which patients reported to manifest with VTE did not receive ART.2 Advanced HIV disease may be another risk factor for the development of thromboses, perhaps due to an increased inflammatory state or the presence of concurrent comorbidities, such as infections.2

In the Strategies for Management of Antiretroviral Therapy (SMART) trial, mortality from non-AIDS events such as cardiovascular disease was found to be higher for participants randomized to intermittent, CD4-guided ART (drug conservation arm) than to continuous ART (viral suppression arm).3 This resulted in researchers stopping the trial prematurely. An increased risk of death was associated with higher levels of high-sensitivity C-reactive protein (hsCRP), interleukin 6 (IL-6), and D-dimers. IL-6 and D-dimer increased at 1 month by 30% and 16%, respectively, in the drug conservation arm but by only 0% and 5%, respectively, in the viral suppression arm (P < .0001). Moreover, the increases in these inflammatory/thrombotic markers in the drug conservation arm were related to HIV RNA levels at 1 month (P < .0001). These findings led the investigators to suggest that HIV-induced activation of inflammation and a hypercoagulable state increases the risk of death among HIV-positive patients, and that interrupting ART further increases this risk.5

Funderburg et al suggest that the increased risk for coagulation in HIV-infected persons may be related to increased expression of the procoagulant tissue factor (TF, thromboplastin). They further demonstrate that monocyte expression of TF correlates with HIV RNA and D-dimer levels in plasma. A total of 60 HIV-infected patients in this study were analyzed, whom the investigators subdivided into viremic (28 patients) and aviremic (32 patients) groups, depending on whether their HIV viremia was above or below 400 copies/mL of HIV RNA. Although they mention that 13 of their patients (46%) in the viremic group were on highly active antiretroviral therapy, their paper failed to report whether ART in this subgroup in any way influenced their findings.

Recent findings suggest that, in addition to HIV viral replication, other factors (eg, micro-bial translocation) could drive immune activation.3 Accordingly, it is of great interest that Funderburg et al demonstrate that the bacterial Toll-like receptor, ligands lipopolysaccharide from *Escherichia coli* and flagellin from *Salmonella typhimurium*, induced monocyte TF expression in vitro. On the basis of their findings, these investigators propose that direct activation of monocytes by microbial products (eg, via bacterial translocation from the gut) may be a key player in promoting thrombosis in HIV infection.1

The findings of Funderburg et al bring us ever closer to elucidating the mechanism by which HIV infection promotes thrombosis. More work in this field is needed, including the use of TF+ monocytes as a potential thrombotic marker (eg, for DVT prophylaxis) among HIV-infected patients, and the justification for using immunomodulators as adjuvant therapy to ART.

**Conflict-of-interest disclosure:** The authors declare no competing financial interests.

**REFERENCES**

1. Funderburg NT, Mayne E, Sieg SF, et al. Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. *Blood.* 2010;115(2):161-167.

2. Crum-Cianflone NF, Weeke J, Bavaro M. Review: thromboses among HIV-infected patients during the highly active antiretroviral therapy era. *AIDS Patient Care STDS.* 2008;22(10):771-778.

3. Eyal A, Veller M. HIV and venous thrombotic events. *S Afr J Surg.* 2009;47(2):54-56.

4. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD, et al. CD4+ count-guided interruption of antiretroviral therapy. *N Engl J Med.* 2006;355(22):2283-2296.

5. Kuller LH, Tracy R, Bélósso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. *PLoS Med.* 2008;5(10):e203.

6. García F, Fumero E, Gatell JM. Immune modulators and treatment interruption. *Curr Opin HIV AIDS.* 2008;3(2):124-130.

---

**PLATELETS & THROMBOPOIESIS**

*From a bleeding disorder: a mutation in the TxA2 R gene, leading to a D304N substitution.***

**Comment on Mumford et al, page 363**

**A bleeding disorder is born**

David Varon Hadassah-Hebrew University Medical Center

In this issue of *Blood*, Mumford and colleagues report a D304N variant of the thromboxane A2 receptor (TxA2 R) in a patient with a bleeding diathesis.1 In their report, they describe the exciting path of a research journey initiated by a clinical observation, and leading to a discovery of a novel mechanism of a bleeding disorder: a mutation in the TxA2 R gene, leading to a D304N substitution. This mutation leads to a loss of function of the receptor due to reduced ligand binding.

Searching for the cause of a bleeding disorder may become quite frustrating in patients who have normal screening tests of coagulation and platelet function. Many such cases are left with the presumptive diagnosis of an “undefined bleeding disorder,” with general hemostatic support as the only therapeutic modality.

Our current screening tools for investigating primary hemostasis-related bleeding disorders are limited to platelet aggregometry (usually induced by ADP, epinephrine, collagen, ristocetin, and arachidonic acid), as well as testing von Willebrand factor antigen and activity. This limitation explains the quite frequent event of a “final”
diagnosis of undefined primary hemostatic disorder. Only highly qualified centers where more specific tests are available may take on the task of further evaluation. The platelet physiology subcommittee of the International Society of Thrombosis and Haemostasis (ISTH) has dedicated its work during recent years to searching for ways to improve and standardize platelet function testing, applying platelet aggregometry, the PFA-100 device, and a proteomics approach.2-4

This report also raises the issue of the gap between genotype and phenotypic expression in hereditary diseases. The D304N substitution was observed in the index patient, who presented with mild bleeding symptoms, and in his father, who had no history of bleeding. As in other cases, a search for modifier genes and for other factors might shed light on this differential phenotypic expression. Thus, the genetic background of a disease does not always explain all phenotypes, and a search for genetic and environmental modifiers should be considered for a more comprehensive understanding of this entity.

Improved understanding of the complex, multiple pathways of platelet activation is significantly contributing to the development of new antiplatelet drugs. Antiplatelet drug therapy is currently undergoing a dramatic revolution, including novel observations on platelet drug resistance, more refined dose adjustment, and development of more potent and safer new drugs.5 One such example is the development of new TxA2 R inhibitors. Such inhibitors are potentially more effective than aspirin because of their inhibitory effect on endothelial cell TxA2 R as well.

Acknowledgment: The author thanks Dr D. Rand for helpful suggestions.

Conflict-of-interest disclosure: The author declares no competing financial interests.

REFERENCES
1. Mumford AD, Dawood BB, Daly ME, et al. A novel thromboxane A2 receptor D304N variant that abrogates ligand binding in a patient with a bleeding diathesis. Blood. 2010;115(2):363-369.
2. Cattaneo M, Hayward CP, Moffat KA, et al. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH. J Thromb Haemost. 2009(6):1029.
3. Hayward CP, Harrison P, Cattaneo M, et al. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost. 2006(2):312-319.
4. Watson SP, Bahou WF, Fitzgerald D, et al. Mapping the platelet proteome: a report of the ISTH Platelet Physiology Subcommittee. J Thromb Haemost. 2005(9):2098-2101.
5. Varen D, Spectre G. Antiplatelet agents. Hematology Am Soc Hematol Educ Program. 2009;267-272.
6. Chou KC. Coupling interaction between thromboxane A2 receptor and alpha-13 subunit of guanine nucleotide-binding protein. J Proteom Res. 2005(4):1681-1686.
A bleeding disorder is born

David Varon